NHS England strikes deal for ground-breaking CAR-T therapy in a new European first
Adult cancer patients in England will receive the new game-changing CAR-T therapy Yescarta® under the first negotiated deal of its kind struck in Europe.
Adult cancer patients in England will receive the game-changing CAR-T therapy Yescarta® (axicabtagene ciloleucel), under the first negotiated deal of its kind struck in Europe.
This is the first time adult patients will have access to CAR-T via the National Health Service (NHS), and follows a deal NHS England reached last month to make Kymriah® available for children and young people with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
“CAR-T cell therapy is one of the most promising new treatments in a generation for lymphoma and leukaemia, and NHS patients will now be among the first in the world to benefit,” explained Simon Stevens, chief executive, NHS England (UK).